

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 体内研究 | Fezolinetant is an antagonist of the neurokinin 3 receptor (NK3R), used for the treatment of menopausal hot flushes[1]. Fezolinetant (ESN364), administered as a 1 mg/kg intravenous (iv) bolus, transiently suppresses the regular, pulsatile release of luteinizing hormone (LH) in ovarectomized ewes, affecting the LH pulse pattern across all examined subjects. Oral administration of ESN364 at 5 mg/kg diminishes plasma LH levels, albeit without influencing follicle-stimulating hormone (FSH), in castrated monkeys. Further, doses of ESN364 (10, 25, 50 mg/kg, orally) inhibit the LH surge and reduce ovarian hormone concentrations throughout the menstrual cycle in monkeys[1]. |
| Concentration | Treated Time | Description | References | |
| human recombinant cytochrome P450 enzymes | 3 μmol/L | 15 minutes | Evaluate the metabolic activity of Fezolinetant to form ES259564 via CYP1A2, CYP2C9, and CYP2C19 | J Clin Pharmacol. 2025 Apr;65(4):508-519 |
| Administration | Dosage | Frequency | Description | References | ||
| Healthy postmenopausal women | Oral | 30 mg | Single dose | Assess the effect of fluvoxamine and smoking on the pharmacokinetics of Fezolinetant and its metabolite ES259564 | J Clin Pharmacol. 2025 Apr;65(4):508-519 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.79mL 0.56mL 0.28mL |
13.95mL 2.79mL 1.40mL |
27.90mL 5.58mL 2.79mL |
|
| CAS号 | 1629229-37-3 |
| 分子式 | C16H15FN6OS |
| 分子量 | 358.39 |
| SMILES Code | O=C(C1=CC=C(F)C=C1)N2[C@H](C)C3=NN=C(C4=NC(C)=NS4)N3CC2 |
| MDL No. | MFCD30532641 |
| 别名 | ESN-364 |
| 运输 | 蓝冰 |
| InChI Key | PPSNFPASKFYPMN-SECBINFHSA-N |
| Pubchem ID | 117604931 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 18 mg/mL(50.22 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1